The randomized phase 0 BR-009 trial was designed for that purpose (Figure 2B): treatment-naïve early HER2-negative breast cancer patients received a single bevacizumab dose preceded and followed by FDG-PET to detect vascular normalization, and then were randomized to receive three weekly ME-344 or placebo doses [41]. This evidence concerns the gene ERBB2 and breast carcinoma.